PMA device
VenaSeal Closure System
Medtronic Vascular, Inc. · Agent, Occluding, Vascular, Permanent (PJQ, Class III) · First FDA decision Feb 20, 2015, newest May 20, 2025Varicose veins and venous insufficiency
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
4
Naming "VenaSeal"
MAUDE reports
191
Brand "VenaSeal", since 2015
PubMed studies
77
Mentioning "VenaSeal"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VenaSeal Closure System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- VenaSeal Closure SystemPMA supplement
P140018-S044 · Decided May 20, 2025 · 279 days after receipt · Normal 180 Day Track
Device type: Agent, occluding, vascular, permanent (PJQ) · Cardiology
- VenaSeal Closure SystemPMA supplement
P140018-S018 · Decided Jan 25, 2020 · 89 days after receipt · Normal 180 Day Track
Device type: Agent, occluding, vascular, permanent (PJQ) · Cardiology
- VenaSeal Closure SystemPMA supplement
P140018-S008 · Decided Jan 30, 2018 · 179 days after receipt · Normal 180 Day Track
Device type: Agent, occluding, vascular, permanent (PJQ) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "VenaSeal", any status and sponsor, newest update first.
- VenaSeal Spectrum: Global Post-Market Randomized Controlled TrialPivotal-lookingTerminated
Medtronic EndovascularPublic (MDT)
NCT03820947 · 506 participants · Start Feb 5, 2020 · Primary completion Jun 12, 2024
Device: VenaSeal™ System; Endothermal Ablation (ETA) · For: Venous Reflux
Sites: Prescott Valley, Arizona; Tucson, Arizona; Fresno, California · 32 sites in all
Medtronic EndovascularPublic (MDT)
NCT03455699 · 114 participants · Start Jul 2016 · Primary completion Jan 2019
Device: VenaSeal SCS; ClosureFast Radiofrequency Ablation (RFA) and 1 more · For: Great Saphenous Vein (GSV) With Venous Reflux Disease
Sites: Scottsdale, Arizona; San Diego, California; Greenwood Village, Colorado · 9 sites in all
- VenaSeal Sapheon Closure System Pivotal Study (VeClose)Pivotal-lookingCompleted
Medtronic EndovascularPublic (MDT)
NCT01807585 · 242 participants · Start Mar 2013 · Primary completion Dec 2013
Device: VenaSeal SCS; ClosureFast Radiofrequency Ablation (RFA) and 1 more · For: Great Saphenous Vein (GSV) With Venous Reflux Disease
Sites: Scottsdale, Arizona; San Diego, California; Greenwood Village, Colorado · 10 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VenaSeal", and for the whole product code for context.
This brand
191 reports: 19 malfunction, 167 injury, 4 death
Whole product code PJQ
1,343 reports: 80 malfunction, 1,243 injury, 19 death
Newest reports for this brand
- VENASEAL CLOSURE SYSTEMInjury
1282497-2026-00061 · Received Oct 28, 2026 · Event dated Mar 18, 2026
Device type: Agent, Occluding, Vascular, Permanent (PJQ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Pain; Skin Discoloration
- VENASEAL CLOSURE SYSTEMInjury
9612164-2026-05084 · Received Oct 13, 2026
Device type: Agent, Occluding, Vascular, Permanent (PJQ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Pain; Embolism/Embolus; Thrombosis/Thrombus
- VENASEAL CLOSURE SYSTEMMalfunction
9612164-2026-04866 · Received Sep 28, 2026 · Event dated Aug 31, 2026
Device type: Agent, Occluding, Vascular, Permanent (PJQ)
Device problem as coded: Deformation Due to Compressive Stress; Detachment of Device or Device Component; Material Deformation
Patient problem as coded: Embolism/Embolus
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- VenaSeal Closure SystemTerminated
Z-1564-2021 · Started Mar 23, 2021
Reason given: Firm received increased number of reports that VenaSeal dispensing systems are not effectively advancing the adhesive forward through the delivery catheter.
Cause as FDA categorized it: Device Design · Device type: Agent, Occluding, Vascular, Permanent (PJQ)
Z-1599-2015 · Started Apr 28, 2015 · Posted by FDA May 12, 2015
Reason given: Possible sterility breach of the outer packaging (pouch) material which may compromise the outside surface sterility of the sealed inner tray.
Cause as FDA categorized it: Package design/selection · Device type: Agent, Occluding, Vascular, Permanent (PJQ)
Published research
The most relevant PubMed records for "VenaSeal"[tiab]. The summary above synthesizes these.
- Superficial Venous Disease-An Updated Review.
Anuforo A, Evbayekha E, Agwuegbo C, et al. · Ann Vasc Surg · 2024Review
- A Comparison of Venaseal Versus Radiofrequency Ablation Outcomes Within a Managed Care Organization.
Lim C, Hsu J, Vo T, et al. · Ann Vasc Surg · 2024
- Sapheon: the solution?
Lawson J, Gauw S, van Vlijmen C, et al. · Phlebology · 2013Review
- Network meta-analysis to compare VenaSeal with other superficial venous therapies for chronic venous insufficiency.
Kolluri R, Chung J, Kim S, et al. · J Vasc Surg Venous Lymphat Disord · 2020Research Support, Non-U.S. Gov't, Systematic Review
- Comparative analysis of VenaBlock and VenaSeal Systems for catheter-guided endovenous cyanoacrylate closure in treating chronic venous insufficiency of the lower extremity: effectiveness and feasibility.
Bozkurt AK, Balkanay OO, Dinc R · Int Angiol · 2024Comparative Study
- Real-world short-term VenaSeal ablation outcomes for symptomatic saphenous incompetence.
Bahi M, Guazzo L, Taumoepeau L · Vascular · 2023
- Corrigendum to "VenaBlock® and VenaSeal® class III cyanoacrylate products are effective and safe in varicose vein treatment".
Phlebology · 2024Published Erratum
- VenaBlock® and VenaSeal® class III cyanoacrylate products are effective and safe in varicose vein treatment.
Dinc R · Phlebology · 2024Letter
- Allergic Contact Dermatitis to VenaSeal: A Sticky Situation.
Fontane Hoyos CN, Guo LN, Boos J, et al. · Dermatitis · 2024Case Reports
- The need for perforator treatment after VenaSeal and ClosureFast endovenous saphenous vein closure in CEAP 6 patients.
Kiguchi MM, Reynolds KB, Cutler B, et al. · J Vasc Surg Venous Lymphat Disord · 2021Comparative Study, Multicenter Study
- Initial Outcomes of Cyanoacrylate Closure, VenaSeal System, for the Treatment of the Incompetent Great and Small Saphenous Veins.
Park I · Vasc Endovascular Surg · 2017
- Hypersensitivity reactions following vein closure therapy with venasealTM (n-butyl- 2-cyanoacrylate).
Lanakiev A, Codispodi CD, Patel PD · Vascular · 2024Case Reports
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.